Evidence map›Paper›PMID 27638904›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2016

Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury.

Jiping Zhao, Hao Yu, Yudong Liu, Sara A Gibson, Zhaoqi Yan, Xin Xu, Amit Gaggar, Pui-Kai Li, Chenglong Li, Shi Wei and 2 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04359290 (Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study), which is not on this map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04359290 phase2completednot on this mapstarted 2020, after this paper: background citation

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study

TypeinterventionalSponsorPhilipps University MarburgRan2020 to 2021Enrolled15ConditionsARDS, Human, COVIDArmsRuxolitinib administration
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 193 citations in OpenAlex.

  1. Article
  2. Article
  3. ACT001 alleviates sepsis-induced acute lung injury by downregulating PANoptosis via the JAK2/STAT3 pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Polymethoxyflavones extracted fromFrontiers in pharmacology · 2025
    Article
  19. Exosome Secretion Regulation in Mice with Acute Lung Injury.Journal of inflammation research · 2025
    Article
  20. Regulatory role of microRNAs in virus-mediated inflammation.Journal of inflammation (London, England) · 2024
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Jiping ZhaoDepartment of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Hao YuDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Yudong LiuDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Sara A GibsonDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Zhaoqi YanDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Xin XuDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Amit GaggarDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Pui-Kai LiDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio.
Chenglong LiDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio.
Shi WeiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Etty N BenvenisteDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Hongwei QinDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama; hqin@uab.edu.ORCID 0000-0002-7511-5078
University of Alabama at Birmingham · USThe Ohio State University · US

Funding

IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
A Novel Proteolytic System of Pulmonary InflammationR01HL102371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAGGAR, AMIT · 2010 to 2021
$3.3M
Therapeutic Intervention of the JAK/STAT Pathway for NeuroinflammationR01NS057563 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BENVENISTE, ETTY N · 2008 to 2017
$2.7M
NHLBI NIH HHS R01 HL102371NIAID NIH HHS T32 AI007051NIAMS NIH HHS P30 AR048311NINDS NIH HHS R01 NS057563
6 · The paper itself

Abstract

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are diseases with high mortality. Macrophages and neutrophils are responsible for inflammatory responses in ALI and ARDS, which are characterized by excessive production of proinflammatory mediators in bronchoalveolar lavage fluid (BALF) and plasma. Aberrant activation of the JAK/STAT pathway is critical for persistent inflammation in many conditions such as infection and autoimmunity. Given the importance of the STAT3 transcription factor in activating macrophages and neutrophils and augmenting inflammation, we investigated the therapeutic potential of inhibiting STAT3 activity using the small-molecule STAT3 inhibitor, LLL12. Our results demonstrate that LPS induces STAT3 activation in macrophages in vitro and in CD45

Indexed as

Acute Lung InjuryAnimalsAnthraquinonesBronchoalveolar Lavage FluidCell SeparationChemokinesDisease Models, AnimalGene DeletionGene Expression RegulationHumansInflammationInflammation MediatorsIntegrasesLeukocytes, MononuclearLipopolysaccharidesMacrophagesAnthraquinonesChemokinesCre recombinaseInflammation MediatorsIntegrasesLipopolysaccharidesLLL12 compoundSocs3 protein, mouseSTAT3 Transcription FactorSulfonamidesSuppressor of Cytokine Signaling 3 Proteinacute lung injuryJAK/STAT pathwaysuppressor of cytokine signaling-3, STAT3 inhibitor

Identifiers

PMID27638904
PMCPMC5130536
OpenAlexW2519120359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.